Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Lengauer

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Cancer Discovery|April 17, 2018
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven CancersVivek Subbiah, Justin F Gainor, Rami Rahal, et al.
Science Translational Medicine|November 3, 2017
A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutationsErica K Evans, Alexandra K Gardino, Joseph L Kim, et al.
Science Translational Medicine|October 1, 2010
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastomaSilvia Buonamici, Juliet Williams, Michael Morrissey, et al.
Journal of Medicinal Chemistry|April 25, 2012
Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancersVictor Certal, Frank Halley, Angela Virone-Oddos, et al.
Science Translational Medicine|May 29, 2024
An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressivaAlison J Davis, Natasja Brooijmans, Jason D Brubaker, et al.
Nature|September 18, 2009
Tankyrase inhibition stabilizes axin and antagonizes Wnt signallingShih-Min A Huang, Yuji M Mishina, Shanming Liu, et al.
Journal of Medicinal Chemistry|January 7, 2014
Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancersVictor Certal, Jean-Christophe Carry, Frank Halley, et al.
Cancer Discovery|October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaRichard D Kim, Debashis Sarker, Tim Meyer, et al.
Science (New York, N.Y.)|April 30, 2020
Feasibility of blood testing combined with PET-CT to screen for cancer and guide interventionAnne Marie Lennon, Adam H Buchanan, Isaac Kinde, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Cancer Discovery|April 17, 2018
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven CancersVivek Subbiah, Justin F Gainor, Rami Rahal, et al.
Science Translational Medicine|November 3, 2017
A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutationsErica K Evans, Alexandra K Gardino, Joseph L Kim, et al.
Science Translational Medicine|October 1, 2010
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastomaSilvia Buonamici, Juliet Williams, Michael Morrissey, et al.
Journal of Medicinal Chemistry|April 25, 2012
Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancersVictor Certal, Frank Halley, Angela Virone-Oddos, et al.
Science Translational Medicine|May 29, 2024
An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressivaAlison J Davis, Natasja Brooijmans, Jason D Brubaker, et al.
Nature|September 18, 2009
Tankyrase inhibition stabilizes axin and antagonizes Wnt signallingShih-Min A Huang, Yuji M Mishina, Shanming Liu, et al.
Journal of Medicinal Chemistry|January 7, 2014
Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancersVictor Certal, Jean-Christophe Carry, Frank Halley, et al.
Cancer Discovery|October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaRichard D Kim, Debashis Sarker, Tim Meyer, et al.
Science (New York, N.Y.)|April 30, 2020
Feasibility of blood testing combined with PET-CT to screen for cancer and guide interventionAnne Marie Lennon, Adam H Buchanan, Isaac Kinde, et al.
Pageof 8